Journal of the National Cancer Institute
-
J. Natl. Cancer Inst. · Feb 2009
Randomized Controlled Trial Multicenter StudyPotential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.
The identification of surrogate endpoints for prostate cancer-specific survival may shorten the length of clinical trials for prostate cancer. We evaluated distant metastasis and general clinical treatment failure as potential surrogates for prostate cancer-specific survival by use of data from the Radiation Therapy and Oncology Group 92-02 randomized trial. ⋯ Distant metastasis and general clinical treatment failure at 3 years may be candidate surrogate endpoints for prostate cancer-specific survival at 10 years. These endpoints, however, must be validated in other datasets.